checkAd

     177  0 Kommentare Santhera Publishes Annual Report 2023


    Ad hoc announcement pursuant to Art. 53 LR

    Pratteln, Switzerland, May 28, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2023 with fully audited results for the year ended December 31, 2023.

    Santhera’s Annual Report 2023 provides comprehensive and detailed information on the Company, its strategy, business, financial performance, governance and compensation in 2023, and confirms the preliminary unaudited 2023 annual results which were published on April 25, 2024. The Annual Report 2023 is available for download on the Company’s website at www.santhera.com/financial-reports.

    Corporate calendar
    June 18, 2024        Annual General Meeting

    About Santhera
    Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), and in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals, Inc. and for China to Sperogenix Therapeutics. For further information, please visit www.santhera.com.

    AGAMREE is a trademark of Santhera Pharmaceuticals.

    For further information please contact:
    public-relations@santhera.com or
    Eva Kalias, Head Investor Relations & Communications
    Phone: +41 79 875 27 80
    eva.kalias@santhera.com

    Disclaimer / Forward-looking statements
    This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

    # # #

    Attachment




    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Santhera Publishes Annual Report 2023 Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 28, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2023 with fully audited results for the year ended December 31, 2023. Santhera’s …